Biomarker hub
FGFR2 fusion
FGFR2 fusions are common in cholangiocarcinoma and often guide targeted therapy trials.
Trials mentioning fgfr2View all trials
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
RECRUITING · Phase not listed
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
COMPLETED · Phase not listed
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RECRUITING · Phase not listed
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
NOT_YET_RECRUITING · Phase not listed
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
RECRUITING · Phase not listed
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
ACTIVE_NOT_RECRUITING · Phase not listed
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RECRUITING · Phase not listed
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
TERMINATED · Phase not listed
Futibatinib in Patients With Specific FGFR Aberrations
TERMINATED · Phase not listed
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
TERMINATED · Phase not listed
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
COMPLETED · Phase not listed
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
NOT_YET_RECRUITING · Phase not listed
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
TERMINATED · Phase not listed
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
TERMINATED · Phase not listed
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
TERMINATED · Phase not listed
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
APPROVED_FOR_MARKETING · Phase not listed
A Phase 2 Clinical Study of ABSK061 and ABSK043
RECRUITING · Phase not listed
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
NOT_YET_RECRUITING · Phase not listed
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
COMPLETED · Phase not listed
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
RECRUITING · Phase not listed
Papers mentioning fgfr2View all papers